(Reuters) - Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics ...

Bio-Rad Laboratories (BIO) has expanded its collaboration with Biodesix, aiming to clinically validate and pursue regulatory approval for cancer biomarker diagnostic assays. The partnership highlights ...

(Reuters) - Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's ...

Diagnostics company Bio-Rad has been sued by the California Institute of Technology for allegedly misusing the school's patented technology for analyzing biological samples. October 30, 2024 Bio-Rad ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on October 23 and set a price target of $446.00. The company’s shares closed yesterday at ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick ...